Orthofix Medical Inc. (NASDAQ:OFIX) Repositions Spine Business While Near-Term Price Action Shows Mixed Signals

Orthofix shows operational rebalancing and a quarter marked by a small EPS beat amid negative cash generation; technicals point to limited trend strength and a bias toward consolidation with event-driven directional risk.

Recent News

May 5, 2026 — Orthofix reported first-quarter 2026 results, highlighted execution after recent spine commercial channel actions and reaffirmed full‑year 2026 financial guidance; the company excluded the impact of discontinued M6™ product lines in pro forma measures. April 9, 2026 — Orthofix released preliminary, unaudited net sales results for Q1 and announced strategic actions in its spine business. February–March 2026 — management realigned spine leadership and scheduled investor conference participation through March.

Technical Analysis

Directional indicators: ADX reads 18.38, signaling no established trend; DI+ shows a dip & reversal while DI- shows a peak & reversal, a combination that implies directional pressure recently shifted toward bullish readings even though trend strength remains weak.

MACD and signal: MACD sits at -0.04 with a peak & reversal in momentum, a condition that represents bearish momentum; however MACD currently sits above its signal line (-0.06), which registers as a bullish MACD cross. The simultaneous peak-and-reverse momentum and a recent cross above the signal line imply short-term tug-of-war between fading momentum and a potential bullish trigger if the cross holds.

MRO: The Momentum/Regression Oscillator at 25.64 with a peak & reversal indicates price sits above the modeled target and carries a tendency toward a correction; the peak & reversal framing emphasizes near-term downside risk to price relative to target levels.

RSI and price structure: RSI at 46.14 with a dip & reversal suggests a move away from oversold conditions but below 50, consistent with consolidation rather than directional breakout. Price closed at $12.01, slightly above the 20-day average ($11.98) and just below the 50-day average ($12.05), while trading well under the 200-day average ($13.89). Bollinger bands place the mid‑range between $11.68 and $12.29 (1x std dev); current price sits near the band center, supporting a near-term sideways bias.

Volume and volatility: Recent volume of 221,526 trails the 10‑day average (397,586) and the 200‑day average (290,127), indicating muted conviction in the latest price moves. 42‑day and 52‑week volatility metrics remain low, and short‑term EMAs show a dip & reversal pattern, reinforcing the view of limited trend momentum unless accompanied by fresh news catalysts.

 


Fundamental Analysis

Revenue and margins: Total revenue totaled $196,708,000 with year‑over‑year revenue growth of 3.38% and quarter‑over‑quarter revenue change of -2.52%. Gross margin sits at 70.94%, above the industry peer mean of 65.18% and industry peer median of 66.06%, reflecting strong product-level profitability.

Profitability and earnings: Operating income and EBIT remain negative at -$13,686,000 and -$15,170,000 respectively, producing an EBIT margin of -7.71%, materially below the industry peer mean EBIT margin of 23.84% and industry peer median of 24.06%. EPS came in at -$0.11 versus an estimate of -$0.29, a beat of $0.18 or roughly 62.07% (EPS surprise ratio 62.07%). Net income for the period totaled -$20,908,000, with operating cash flow negative at -$17,610,000 and free cash flow negative at -$28,271,000.

Balance sheet and liquidity: Cash and short‑term investments total $120,278,000, supporting a current ratio of 2.87, a quick ratio of 1.76 and a cash ratio of 0.75. Net debt stands at $101,057,000 against market capitalization of $507,789,112. Debt‑to‑equity equals 0.60 and debt‑to‑assets equals 0.296. Interest coverage reads -2.68, reflecting negative operating income and constrained coverage of interest expense.

Capital efficiency and working capital: Cash conversion cycle exceeds 233 days versus an industry peer mean of about 155 days, indicating elongated working capital deployment relative to peers. Asset turnover registers 0.226, above the industry peer mean of 0.12038, while receivables and inventory turnover show sequential softness.

Valuation and WMDST view: Price multiples convey mixed signals. Price‑to‑book at 1.17 sits below the industry peer mean (about 5.94) and industry peer median (about 4.17). Free cash flow yield registers at approximately -5.57%, below the industry peer mean of roughly 0.57%. The current valuation as determined by WMDST: over‑valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-05-05
NEXT REPORT DATE: 2026-08-04
CASH FLOW  Begin Period Cash Flow 85.1 M
 Operating Cash Flow -17.61 M
 Capital Expenditures -10.66 M
 Change In Working Capital -22.39 M
 Dividends Paid
 Cash Flow Delta 35.8 M
 End Period Cash Flow 120.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 196.7 M
 Forward Revenue -20.30 M
COSTS
 Cost Of Revenue 57.2 M
 Depreciation 14.6 M
 Depreciation and Amortization 14.6 M
 Research and Development 15.3 M
 Total Operating Expenses 210.4 M
PROFITABILITY
 Gross Profit 139.5 M
 EBITDA -619.00 K
 EBIT -15.17 M
 Operating Income -13.69 M
 Interest Income
 Interest Expense 5.7 M
 Net Interest Income -5.66 M
 Income Before Tax -20.83 M
 Tax Provision 74.0 K
 Tax Rate 40.0 %
 Net Income -20.91 M
 Net Income From Continuing Operations -20.91 M
EARNINGS
 EPS Estimate -0.29
 EPS Actual -0.11
 EPS Difference 0.18
 EPS Surprise 62.069 %
 Forward EPS 0.21
 
BALANCE SHEET ASSETS
 Total Assets 886.6 M
 Intangible Assets 264.3 M
 Net Tangible Assets 170.9 M
 Total Current Assets 461.5 M
 Cash and Short-Term Investments 120.3 M
 Cash 120.3 M
 Net Receivables 137.8 M
 Inventory 177.8 M
 Long-Term Investments 13.9 M
LIABILITIES
 Accounts Payable 54.7 M
 Short-Term Debt
 Total Current Liabilities 161.0 M
 Net Debt 101.1 M
 Total Debt 262.3 M
 Total Liabilities 451.4 M
EQUITY
 Total Equity 435.2 M
 Retained Earnings -389.24 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 10.78
 Shares Outstanding 40.382 M
 Revenue Per-Share 4.87
VALUATION
 Market Capitalization 507.8 M
 Enterprise Value 649.8 M
 Enterprise Multiple -1049.703
Enterprise Multiple QoQ -2829.314 %
Enterprise Multiple YoY 1593.175 %
Enterprise Multiple IPRWA high: 100.974
median: 73.295
mean: 72.274
low: -114.515
OFIX: -1049.703
 EV/R 3.303
CAPITAL STRUCTURE
 Asset To Equity 2.037
 Asset To Liability 1.964
 Debt To Capital 0.376
 Debt To Assets 0.296
Debt To Assets QoQ 41.018 %
Debt To Assets YoY 26.318 %
Debt To Assets IPRWA high: 0.725
OFIX: 0.296
mean: 0.243
median: 0.221
low: 0.006
 Debt To Equity 0.603
Debt To Equity QoQ 51.991 %
Debt To Equity YoY 43.279 %
Debt To Equity IPRWA high: 4.524
OFIX: 0.603
mean: 0.469
median: 0.426
low: 0.007
PRICE-BASED VALUATION
 Price To Book (P/B) 1.167
Price To Book QoQ -7.153 %
Price To Book YoY -11.719 %
Price To Book IPRWA high: 16.868
mean: 5.938
median: 4.172
OFIX: 1.167
low: 1.093
 Price To Earnings (P/E) -114.315
Price To Earnings QoQ -293.233 %
Price To Earnings YoY -40.974 %
Price To Earnings IPRWA high: 194.313
mean: 122.341
median: 80.164
OFIX: -114.315
low: -374.46
 PE/G Ratio 0.784
 Price To Sales (P/S) 2.581
Price To Sales QoQ 0.374 %
Price To Sales YoY -17.475 %
Price To Sales IPRWA high: 62.134
mean: 34.497
median: 23.992
OFIX: 2.581
low: 0.285
FORWARD MULTIPLES
Forward P/E 61.185
Forward PE/G -0.42
Forward P/S -25.012
EFFICIENCY OPERATIONAL
 Operating Leverage 76.072
ASSET & SALES
 Asset Turnover Ratio 0.226
Asset Turnover Ratio QoQ -13.33 %
Asset Turnover Ratio YoY 0.363 %
Asset Turnover Ratio IPRWA high: 0.401
OFIX: 0.226
mean: 0.12
median: 0.118
low: 0.071
 Receivables Turnover 1.438
Receivables Turnover Ratio QoQ -12.829 %
Receivables Turnover Ratio YoY -0.997 %
Receivables Turnover Ratio IPRWA high: 3.141
mean: 2.072
median: 1.748
OFIX: 1.438
low: 0.361
 Inventory Turnover 0.327
Inventory Turnover Ratio QoQ -11.05 %
Inventory Turnover Ratio YoY -17.513 %
Inventory Turnover Ratio IPRWA high: 1.226
mean: 0.625
median: 0.525
OFIX: 0.327
low: 0.137
 Days Sales Outstanding (DSO) 63.441
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 233.584
Cash Conversion Cycle Days QoQ -4.677 %
Cash Conversion Cycle Days YoY -5.487 %
Cash Conversion Cycle Days IPRWA high: 587.726
OFIX: 233.584
median: 159.313
mean: 154.818
low: -130.573
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.655
 CapEx To Revenue -0.054
 CapEx To Depreciation -0.733
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 656.5 M
 Net Invested Capital 656.5 M
 Invested Capital 656.5 M
 Net Tangible Assets 170.9 M
 Net Working Capital 300.5 M
LIQUIDITY
 Cash Ratio 0.747
 Current Ratio 2.866
Current Ratio QoQ 17.214 %
Current Ratio YoY 5.823 %
Current Ratio IPRWA high: 8.801
mean: 2.973
OFIX: 2.866
median: 1.9
low: 0.669
 Quick Ratio 1.762
Quick Ratio QoQ 22.828 %
Quick Ratio YoY 17.638 %
Quick Ratio IPRWA high: 7.878
mean: 2.26
OFIX: 1.762
median: 1.518
low: 0.37
COVERAGE & LEVERAGE
 Debt To EBITDA -423.675
 Cost Of Debt 1.542 %
 Interest Coverage Ratio -2.678
Interest Coverage Ratio QoQ -639.755 %
Interest Coverage Ratio YoY -74.66 %
Interest Coverage Ratio IPRWA high: 29.801
median: 20.603
mean: 20.147
OFIX: -2.678
low: -47.147
 Operating Cash Flow Ratio -0.109
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 81.159
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.227 %
 Revenue Growth -10.551 %
Revenue Growth QoQ -251.966 %
Revenue Growth YoY 3.38 %
Revenue Growth IPRWA high: 8.836 %
median: -3.328 %
mean: -6.116 %
OFIX: -10.551 %
low: -31.815 %
 Earnings Growth -145.833 %
Earnings Growth QoQ 2.623 %
Earnings Growth YoY -83.796 %
Earnings Growth IPRWA high: 181.818 %
mean: -6.376 %
median: -13.636 %
low: -136.486 %
OFIX: -145.833 %
MARGINS
 Gross Margin 70.941 %
Gross Margin QoQ -0.214 %
Gross Margin YoY 12.954 %
Gross Margin IPRWA high: 86.474 %
OFIX: 70.941 %
median: 66.064 %
mean: 65.176 %
low: 24.932 %
 EBIT Margin -7.712 %
EBIT Margin QoQ -885.336 %
EBIT Margin YoY -68.644 %
EBIT Margin IPRWA high: 32.927 %
median: 24.063 %
mean: 23.84 %
OFIX: -7.712 %
low: -46.732 %
 Return On Sales (ROS) -6.958 %
Return On Sales QoQ -1425.333 %
Return On Sales YoY -71.71 %
Return On Sales IPRWA high: 32.927 %
mean: 23.265 %
median: 22.584 %
OFIX: -6.958 %
low: -52.292 %
CASH FLOW
 Free Cash Flow (FCF) -28.27 M
 Free Cash Flow Yield -5.567 %
Free Cash Flow Yield QoQ -287.189 %
Free Cash Flow Yield YoY 34.209 %
Free Cash Flow Yield IPRWA high: 1.775 %
mean: 0.568 %
median: 0.47 %
low: -2.732 %
OFIX: -5.567 %
 Free Cash Growth -268.08 %
Free Cash Growth QoQ -146.758 %
Free Cash Growth YoY 1.04 %
Free Cash Growth IPRWA high: 237.037 %
mean: -20.459 %
median: -37.858 %
OFIX: -268.08 %
low: -328.297 %
 Free Cash To Net Income 1.352
 Cash Flow Margin -8.943 %
 Cash Flow To Earnings 0.841
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -2.407 %
Return On Assets QoQ 811.742 %
Return On Assets YoY -61.096 %
Return On Assets IPRWA high: 5.214 %
median: 3.047 %
mean: 2.591 %
OFIX: -2.407 %
low: -8.936 %
 Return On Capital Employed (ROCE) -2.091 %
 Return On Equity (ROE) -0.048
Return On Equity QoQ 872.47 %
Return On Equity YoY -58.533 %
Return On Equity IPRWA high: 0.07
median: 0.047
mean: 0.036
OFIX: -0.048
low: -0.215
 DuPont ROE -4.724 %
 Return On Invested Capital (ROIC) -1.386 %
Return On Invested Capital QoQ -593.238 %
Return On Invested Capital YoY -70.161 %
Return On Invested Capital IPRWA high: 5.501 %
mean: 2.725 %
median: 2.043 %
OFIX: -1.386 %
low: -7.718 %

Six-Week Outlook

Expect consolidation with bias determined by execution updates or channel actions tied to the spine business. Technicals show weak trend strength (ADX <20) with directional indicators recently shifting toward bullish readings but momentum signals (MRO peak & reversal, MACD peak & reversal) favor mean reversion risk. A sustained MACD position above its signal line coupled with recovering volume would support upside continuation; absent those confirmations, price likely trades in a $11.70–$12.80 range while fundamentals—negative operating cash flow and negative free cash flow—remain the primary source of downside risk should near‑term execution disappoint. Monitor management commentary on spine commercial actions and any updated guidance or operational milestones as potential catalysts for a directional breakout or renewed consolidation.

About Orthofix Medical Inc.

Orthofix Medical Inc. (NASDAQ:OFIX) designs and manufactures medical devices for spine and orthopedic applications. Headquartered in Lewisville, Texas, the company operates through two primary segments: Global Spine and Global Orthopedics. The Global Spine segment produces bone growth stimulators and motion preservation and fixation implants, enhancing bone fusion and supporting surgical procedures of the spine. This segment also offers biological products, such as demineralized bone matrices and synthetic bone void fillers, and develops navigation technologies utilizing machine-vision and optical innovations for surgical tools. The Global Orthopedics segment provides solutions for limb reconstruction and deformity correction, offering both external and internal fixation products. These products integrate with digital technologies to support comprehensive patient treatment pathways. Orthofix distributes its products through a network of distributors and sales representatives to hospitals and healthcare providers across the United States and internationally, including countries like Italy, Germany, the United Kingdom, France, and Brazil. Founded in 1980, Orthofix Medical Inc. continues to innovate in the field of spine and orthopedic care, providing advanced solutions to healthcare professionals worldwide.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.